- Home
- FINW vs STTK Comparison
FINW vs STTK Comparison
Compare FINW & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- STTK
- Stock Information
- Founded
- FINW 1999
- STTK 2016
- Country
- FINW United States
- STTK United States
- Employees
- FINW N/A
- STTK N/A
- Industry
- FINW Commercial Banks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- STTK Health Care
- Exchange
- FINW Nasdaq
- STTK Nasdaq
- Market Cap
- FINW 212.8M
- STTK 56.8M
- IPO Year
- FINW 2021
- STTK 2020
- Fundamental
- Price
- FINW $15.33
- STTK $1.12
- Analyst Decision
- FINW Buy
- STTK Hold
- Analyst Count
- FINW 3
- STTK 3
- Target Price
- FINW $18.67
- STTK $2.00
- AVG Volume (30 Days)
- FINW 19.3K
- STTK 182.2K
- Earning Date
- FINW 01-30-2025
- STTK 02-27-2025
- Dividend Yield
- FINW N/A
- STTK N/A
- EPS Growth
- FINW N/A
- STTK N/A
- EPS
- FINW 1.06
- STTK N/A
- Revenue
- FINW $69,509,000.00
- STTK $6,435,000.00
- Revenue This Year
- FINW N/A
- STTK $313.04
- Revenue Next Year
- FINW $10.13
- STTK N/A
- P/E Ratio
- FINW $14.71
- STTK N/A
- Revenue Growth
- FINW 4.87
- STTK 382.75
- 52 Week Low
- FINW $8.72
- STTK $0.94
- 52 Week High
- FINW $20.50
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- FINW 35.07
- STTK 43.75
- Support Level
- FINW $15.51
- STTK $1.13
- Resistance Level
- FINW $16.65
- STTK $1.39
- Average True Range (ATR)
- FINW 0.71
- STTK 0.11
- MACD
- FINW -0.07
- STTK 0.00
- Stochastic Oscillator
- FINW 0.00
- STTK 18.18
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.